Is CFD Overkill for Your Scale-Up? Why It Belongs in Every Biotech Scientist’s Toolkit – Part 1
Can computational fluid dynamics (CFD) join the ranks of everyday tools in bioprocess engineering—right alongside spreadsheets and pH meters?
Why the Cell Line Is the CMC Decision You Don’t Get to Undo – Part 2
Is your next blockbuster biologic doomed before your team even steps into a lab?
Why the Cell Line Is the CMC Decision You Don’t Get to Undo – Part 1
What if your blockbuster biologic stumbled—not because the science wasn’t there, but because no one asked if it could actually be manufactured at scale?
How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics
“Will this novel host replace CHO?” I hear this question often — and I want to be direct with you: I think it’s the wrong question.
Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts)
Is CHO still the host of choice?
Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 2
What happens between scientific discovery and clinical trials?
Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 1
Picture the difference between a “drug” and a true “product”.
Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore – Part 2
What if the biggest advancement in bioprocessing isn’t a new AI algorithm or cutting-edge bioreactor, but a renewed focus on the foundational skills that drive innovation—and a clear-eyed look at what AI can (and can’t) really do for the industry right now?
Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore – Part 1
How do you bridge the gap between cutting-edge industrial bioprocessing and the academic world tasked with training the next generation?
How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds
Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tools